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Abstract Adult-onset Still’s disease (AOSD) is a rare
rheumatological condition characterized by an acute sys-
temic involvement. There are no treatment guidelines. Glu-
cocorticoids (GC), methotrexate (MTX), cyclosporin A and
biologic agents have been successfully used, often in asso-
ciation. We treated six cases of AOSD with clarithromycin
(CM) in combination with low-mild dose of GC and MTX.
Four of them were not responsive to high-dose GC added to
DMARDs, while two of them were treated with low-mild
dose of GC added to CM from the beginning. CM, 500 mg
b.i.d., was added to a mild-low dose of GC and to MTX.
The dose of the drugs was reduced (and stopped where
possible) following clinical and laboratory parameters.
ACR criteria were used to assess clinical improvement. At
6 months 5 patients reached ACR 70% and could stop any
therapy in 6–18 months; 1 continued chronic therapy with
low-dose GC added to CM and MTX to maintain ACR
50%. CM can be a useful drug for the treatment of AOSD,
even in patients not responsive to high-dose GC and
DMARDs. No deWnitive conclusion can be drawn based on
the present study.
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Adult-onset Still’s disease (AOSD) is a rare systemic con-
dition of unknown origin. It is a worldwide reported hetero-
geneous disease, predominantly aVecting young adults
(peak age 16–35), characterized by a sudden onset of high
spiking fever, which often follows a transient pharyngitis or
a maculopapular rush, with a disabling arthritis or arthralgia.
Other common symptoms are: sore throat, lymphoaden-
opathy, hepatosplenomegaly and pericarditis or pleuritis.
Laboratory abnormalities include marked leukocytosis with
neutrophilia, high level of erythrocyte sedimentation rate
(ESR), C-reactive protein (CRP), lactic dehydrogenase
(LDH) and liver function tests [1]. However, a pronounced
increase in serum ferritin and interleukin-18 levels are
probably the most characteristic tests and glycosylated
ferritin has been recently purposed as a helpful marker of
hemophagocytic syndrome [2].
Preliminary criteria for classiWcation of AOSD have
been purposed by Yamaguchi in 1992 consisting in fever,
arthralgia, typical rash and leukocytosis as major, and sore
throat, lymphoadenopathy and/or splenomegaly, liver
dysfunction and the absence of rheumatoid factor and anti-
nuclear antibody as minor criteria. The diagnosis requires
the presence of Wve or more criteria including two or more
major criteria [3].
Because of its low prevalence and its heterogeneous
expression, the treatment of AOSD has no guideline. The
management is Wrst directed at the acute systemic symp-
toms. NSAIDs have been used with scarce eYcacy; while
GCs give clinical response in 76–95% of patients [4]. How-
ever, other treatments in association with GCs or alone are
often needed. By homology with rheumatoid arthritis gold
salt, HCQ, D-penicillamine, sulfasalazine (SSZ), cyclo-
phosphamide (CP) were tested, but only cyclosporin A
(CsA) [5] and methotrexate (MTX) seem to be really eVec-
tive [6] with a GCs sparing eVect. Moreover polyvalent
intravenous immunoglobulin [7] have been successfully
tested in patients with AOSD refractory to GCs. Concern-
ing the pathogenesis of the disease, recent studies have
suggested an important role for interleukin 1 (IL-1), IL-6,
IL-18, macrophage colony-stimulating factor, interferon
gamma and tumor necrosis factor (TNF) [8]. For this rea-
son also anti-TNF- agents have been used showing that
these drugs may be helpful in some AOSD patient, but
most of them achieved only partial remission [4, 9, 10]. On
the other hand, patients with treatment-resistant AOSD
have been successfully treated with anakinra, with reduc-
tion of IL-18 serum levels [11].
In 2004 a case of refractory AOSD successfully treated
with CM was reported [12]. The anti-inXammatory action
of CM is well known [13]. A pilot study on the use of CM
in RA was published in 2002; 18 RA patients unresponsive
to DMARDs were treated with CM for 6 months with suc-
cessful results in 10 of them [14]. CM showed a very rapid
onset of action (10 days) and lowered the plasma levels of
PLA2 and PGE2. More recently, Ogrendik [15] conWrmed
the eYcacy of CM in a double-blind trial versus placebo in
81 RA patients obtaining a signiWcant improvement follow-
ing ACR criteria. In 2006 Moskowitz [16] published a
report of seven patients aVected by undiVerentiated connec-
tive tissues disease (UCTD) successfully treated with CM
in a 12-week open-label study; he also conWrmed the very
rapid onset of action (as early as 1 week).
Methods
Here we report six cases of AOSD, diagnosed following the
criteria of Yamaguchi [3] and treated with CM. Clinical
improvement in disease activity were deWned according to
the ACR criteria for RA. Side eVects either suspected or
certain were noted. Therapy was as follows: at the start of
the study, 500 mg of CM was administered orally b.i.d., it
was then reduced and later stopped following clinical and
laboratory parameters. Methylprednisolone (MP) was used
at mild-low doses (4–16 mg daily), and was then reduced
and stopped whenever possible. MTX at the weekly dose of
15 mg was added in 4 patients while 2 patients (young
females) refused it because of its teratogenicity. All the
patients gave their informed consent to the treatment
according to the Declaration of Helsinki.
Results
All six patients followed Yamaguchi diagnostic criteria for
AOSD. Baseline characteristics are shown in Table 1.
Mean age of patients was 36 § 4.65 years.
Median duration of the disease was 6 months (3–200
months). In four patients this was the Wrst attack of the
disease. In patient no. 2 this was his fourth attack, while in
patient no. 6 this was her third attack.
Following ACR criteria six patients reached an ACR
50% improvement at 6 months, Wve patients an ACR 70%
improvement. Outcomes are shown in Table 2.
Side eVects were: (1) elevated hepatic enzymes in Case
1, due to MTX, that was stopped; (2) nausea in Case 2,
due to MTX, that was stopped; (3) metallic taste in Wve
patients. Only patient no. 5, even in partial remission
(ACR 50%), decided to stop CM because of this side
eVect. This decision caused a Xare (ACR < 20%) in
10 days not controlled by other DMARDs or by increas-
ing GC dose. Consequently, patient no. 5 decided to con-
tinue with CM reaching again the ACR 50% improvement
in a short time.123
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which, in course of the previous ineVective treatment with
high-dose GCs and MTX were as follows : TNF- 28.6 pg/
ml (normal values < 15.6 mg/ml) and IL-6 39.5 pg/ml
(normal values < 12.5 pg/ml). Both TNF- and IL-6 levels
diminished to the normal level after 2 months of the treat-
ment with CM.
In the Case 6 the disease onset was at the age of 16 and
the patient had a second attack at the age of 18. With the
treatment (indomethacin for 6 months) the patient had
Table 1 Baseline characteristics of the patients
RF rheumatoid factor, ANA antinuclear antibodies
Case Sex Age Ferritin 
(ng/ml) 
(n.v. < 150)
ESR 
(mm/h)
Fever Arthralgias 
or arthritis
Rash WBC £ 103/L 
(polynuclear > 75%)
RF ANA Sore 
throat
Lymphadenopathy/
splenomegaly
Liver 
dysfunction
1 M 41 1,530 94 + + ¡ 17,700 ¡ ¡ + ¡ ¡
2 M 30 856 72 + + + 26,200 ¡ ¡ + + +
3 F 23 353 73 + + + 15,100 ¡ ¡ ¡ ¡ +
4 F 44 1,080 124 + + + 18,950 ¡ ¡ + + ¡
5 F 43 990 60 + + ¡ 28,700 ¡ ¡ ¡ + ¡
6 F 35 5,293 99 + + + 15,000 ¡ ¡ ¡ ¡ +
Table 2 Treatment and outcome
PDN prednisone, SSZ sulphasalazine, CS cyclophosphamide, CM clarithromycin, MP methylprednisolone, MTX methotrexate, CsA cyclosporin
A, HCQ hydroxychloroquine
a Months to improvement and months to stop treatment are measured from the start of the treatment with CM
Case Total 
disease 
duration 
(months)
Disease duration 
(in months) 
before treatment 
With CM
Previous 
ineYcacious 
treatment
EYcacious 
treatment
ESR (mm at 1 h) 
changes (in months)
Outcome 
months to 
improvement
Months 
to stop 
treatmenta
1 6 6 MTX 15 mg/week
+ MP 4 mg
CM 500 mg 
b.i.d. + MP 4 mg +
MTX 15 mg/week
94!11 (3 months) 3 months 
ACR 70% 
MTX stopped 
for hepatic 
enzyme 
increase
12
2 60 12 (4th attack) PDN 25 mg + MTX 
15 mg/week
+ HCQ 200 mg
+ SSZ 2,000 mg
CM 500 mg b.i.d.
+ MP 8 mg 
+MTX 15 mg/week
40!7 (6 months) 6 months 
ACR 70% 
MTX stopped 
for nausea
18
3 3 3 – CM 500 mg b.i.d.
+ MP 16 mg
73!15 (2 months) 2 months 
ACR 70%
6
4 6 6 i.v. MP + i.v. CP 
followed by 
MP 32 mg
+ MTX 
15 mg/week
CM 500 mg b.i.d.
+ MP 16 mg 
+MTX 15 mg/week
40!13 (2 months) 2 months 
ACR 70%
7
5 3 3 PDN 12.5 mg
+ MTX 
15 mg/week;
MTX 
15 mg/week
+ CsA 250 mg
+ MP 6 mg
CM 500 mg b.i.d.
+ MP 6 mg
+ MTX 15 mg/week
99!14 (3 months) 3 months 
ACR 50%
chronical 
treatment 
(CM 500 mg
+ MTX 
10 mg/week
+ MP 6 mg)
6 200 1 (3rd attack) – CM 500 mg b.i.d.
+ MP 8 mg
99!10 (3 months) 3 months 
ACR 70%
9123
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any further drug.
Discussion
The etiology of AOSD remains unknown. The design of a
therapeutic scheme is complex since, at the present stage,
the disease has no treatment guidelines. Consequently,
most published papers include small cohorts of case-reports
and only a few papers studied 6–20 patients. Here, we have
described six cases of patients aVected by AOSD that have
been treated with CM added to low-mild dose of GC and
MTX. In all six cases CM has conWrmed to be eYcacious in
AOSD as in other inXammatory rheumatic diseases [12, 14,
16]. Indeed when CM was added to a mild-low dose of GC,
Wve patients achieved a complete remission (ACR 70) and
one patient achieved an incomplete remission (ACR 50%)
at 6 months; Wve patients could stop any treatment in a
mean time of 10 months, while the patient who did not
reach the complete remission is currently chronically
treated with CM, MTX and low-dose GC.
CM compared to biologic agents
In Table 3 our outcomes are compared with those obtained
in other four papers where AOSD was treated with biolo-
gics agents. Our patients had a shorter disease duration, but
higher ESR level and were treated from the beginning with
a low dose of GC. The outcomes obtained with CM are
very close to those obtained with anakinra [11] taking into
account that in both studies most of the patients were
treated with the drug as add-on therapy of MTX, while GC
dosages were lower in our study.
Recent studies showed an important role of cytokines in
the pathogenesis of the disease, but Wrst experiences of
treatment with anti-TNF- blocking agents are not encour-
aging [4, 9, 10]. Fautrel in 2005 [4] reported about 20 cases
of refractory AOSD treated with TNF- blocking agents
where the therapy was discontinued in 11 cases because of
lack of eYcacy, in 4 cases because of side eVects, in further
2 cases for other reasons. If we consider four out of our six
patients as refractory to DMARDs and high-dose GC, we
can note that three of them obtained a complete remission
(ACR 70%) and could stop completely the treatment, while
only one (Case 5) obtained an incomplete remission (ACR
50%) and was obliged to continue the chronic treatment
with CM added to MTX and low-dose GC. In that Case (no.
5) the treatment with CM was temporarily stopped because
of severe metallic taste, the most common side eVect of
CM. However, after stopping CM, patient no. 5 had a
relapse in 10 days. This fact shows once more that CM has
a rapid onset of action and conversely a rapid lack of
eYcacy when stopped [14, 16]. Anyway, as CsA 250 mg
daily added to MTX 17.5 mg/week and MP 10 mg daily
did not give satisfying results (ACR < 20%), the patient
was switched back to CM added to MTX 15 mg/week and
low-dose GC obtaining an incomplete remission (ACR
50%).
Cytokines levels
We detected TNF- and IL-6 levels only in Case 4, where
they were elevated also in the course of the treatment with
high-dose GC and MTX as well as in a previous treatment
with i.v. high dose of GC added to i.v. CP. In this case CM
was able to induce the remission in 2 months reducing the
levels of anti-TNF- and IL-6 to the normal values. This
Wnding is in agreement with current reports about CM
eVectiveness in reducing cytokines independently from its
antibiotic activity [18–20].
GC dose
Cases 2, 4 and 5 were previously treated with high-dose GC
associated with either MTX or other DMARDs without
reaching the remission. In Case 4 the (transient) previous
remission was obtained only with intravenous high dose of
MP (2 g) associated to intravenous CP. However the patient
obtained a complete remission with CM added to a lower
dose of GC in 2–6 months, and then the treatment could be
stopped. In case 2, where high-dose GC added to MTX,
HCQ and SSZ were ineVective, CM obtained the remission
in 6 months adding MTX and low-dose GC. In Case 5 the
treatment with CM was added to a low-dose GC to avoid
worsening diabetes caused by previous, ineVective high
dose of GC.
The Cases 1, 3 and 6 had never been treated with GC.
Case 1 achieved complete remission in a short time using
only 4 mg of MP added to CM. Since Cases 3 and 6 were
two young women, they preferred to exclude MTX from
the beginning; because of its teratogenicity, and use MP at
low-mild dose added to CM instead. Complete remission
was however achieved in only 2–3 months.
Mechanism of action
Ogrendik [15] hypothesizes that the oral anaerobic bacteria
could be important in the etiopathogenesis of RA: he sus-
pects that the eYcacy of the drug could be related to its
antibiotic activity against Gram-negative anaerobic bacteria
considered as responsible for the periodontitis. However if
RA is a bacterial disease, it would be diYcult to justify the
eYcacy of MTX and other immunosuppressant drugs
including GC in RA therapy [17]. On the other hand,
Moskowitz [16] notices that the family of macrolide123
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560 Rheumatol Int (2010) 30:555–560antibiotics has non-antimicrobial eVects. In particular the
response of diVuse panbronchiolitis and other chronic
respiratory infections to long-term macrolide therapy is an
example of the anti-inXammatory and immunomodulatory
activities of these drugs. In addition, CM is able to inhibit
the production of IL-1 and TNF in the lungs and is also
able to inhibit cell mediator release and survival and to
modulate IL-8 levels in chronic sinusitis and asthma [18,
19]. Moreover CM quickly inhibits TNF production in a
mouse model of septic shock, supporting the distinction
between antimicrobial and anti-inXammatory properties of
the drug [20].
Conclusions
Clarithromycin can be a useful drug to treat AOSD,
because of its anti-inXammatory properties independent
from its antibiotic activity. The association of CM with
mild-low dose GC and MTX seems to be acceptable; thus
permitting reduction of doses and administration of other
drugs. Since CM gives a therapeutic advantage with no
serious reported side eVects and acceptable costs, it may
represent a useful and valuable drug to be enclosed in a
therapeutic algorithm for AOSD.
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